Introduction
AcroViz applies diffusion MRI and AI techniques to analyze neuroimages and develop novel image biomarker. Aiming to establish an automatic tract-based analysis technology platform, the go-to-market strategies involve by first providing an innovative brain health assessment service, now available with several prestigious health-check institutions.
The AcroViz Axonal Brain Age examination evaluates microscopic brain axonal degeneration and predict dementia risk, which enables medical doctors and high-risk dementia cohorts an objective and harmless way to monitor brain health longitudinally. The benefits to be able to track brain health objectively before symptoms appear or early cognitive decline are enormous, as presently only prompt and effective intervention may reverse the degeneration, hence prevent the huge pain and burden of dementia.
Next in AcroViz pipeline product includes other clinical-data verified image biomarkers, which has proven statistical significance in predicting the risk and prognosis of dementia, best serving as Mild Cognitive Impairment (MCI) image biomarkers.
Features / strengths
1. Applies diffusion MRI and Machine Learning techniques to analyze neuroimaging, providing the first-to-market microscopic brain axonal integrity assessment technology and service.
2. Evaluate the robustness of whole brain fiber tracts, as well as cognitive function networks including long-term episodic memory & emotion, long-term semantic memory network, long-term semantic memory network, working memory, attention, language, visual and sensorimotor networks.
3. Existing products measure brain gray matter volume that may show brain shrinkage, while AcroViz analyzes white matter tracts in depth.
4. Predict dementia risk before symptoms appear, as presently only prompt and effective intervention may reverse the degeneration.
5. Assist medical doctors to monitor and track longitudinal treatment responses with accurate objective evaluation, especially for early dementia.
6. Technical Milestones Achieved: Obtain the US FDA 510(k) certificate and TFDA permit license.
Specification in detail
Function description
Evaluate brain biological age to assess brain aging and predict dementia risk, including: Axonal brain age of whole brain and of eight cognitive function networks including episodic memory/emotion system, semantic memory system, implicit memory system, working memory system, attention system, language system, somatosensory system, and visual system.
Approval & Certification
US FDA 510(k) certificate
Approval & Certification
TFDA permit licens
